Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Vivos Therapeutics (VVOS) over the last 5 years, with Q3 2025 value amounting to $2.8 million.

  • Vivos Therapeutics' Cash from Financing Activities fell 2703.99% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year decrease of 753.67%. This contributed to the annual value of $17.9 million for FY2024, which is 6365.47% up from last year.
  • Latest data reveals that Vivos Therapeutics reported Cash from Financing Activities of $2.8 million as of Q3 2025, which was down 2703.99% from $3.1 million recorded in Q4 2024.
  • Over the past 5 years, Vivos Therapeutics' Cash from Financing Activities peaked at $25.4 million during Q2 2021, and registered a low of -$1.2 million during Q3 2021.
  • For the 4-year period, Vivos Therapeutics' Cash from Financing Activities averaged around $5.6 million, with its median value being $3.6 million (2023).
  • Within the past 5 years, the most significant YoY rise in Vivos Therapeutics' Cash from Financing Activities was 190479.58% (2021), while the steepest drop was 16440.1% (2021).
  • Over the past 4 years, Vivos Therapeutics' Cash from Financing Activities (Quarter) stood at -$1.2 million in 2021, then skyrocketed by 403.92% to $3.6 million in 2023, then decreased by 14.41% to $3.1 million in 2024, then decreased by 9.53% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $3.1 million for Q4 2024, and $3.8 million during Q3 2024.